Mark Zorbas

Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities

Kanyin E. Zhang, Amy K. Patick, Bradley M. Kerr et al. · Antimicrobial Agents and Chemotherapy · 2001 · 121 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient.

Mitchell E. Gross, Mark Zorbas, Y J Danels et al. · PubMed · 1991 · 95 citations

Life Sciences, Cell Biology, Oncology +15

Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model

Timothy P. LaBranche, Alison M. Bendele, Brian C Omura et al. · Annals of the Rheumatic Diseases · 2016 · 58 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.

Howard L. McLeod, J Cassidy, Robert H. Powrie et al. · PubMed · 2000 · 37 citations

Medicine, Pharmacokinetics, Pharmacology +13

Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene.

Sachin Untawale, Mark Zorbas, Clague P. Hodgson et al. · PubMed · 1993 · 35 citations

Medicine, Molecular Biology, Oncology +17